BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 27511990)

  • 1. Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma.
    Inamura K; Yokouchi Y; Sakakibara R; Kobayashi M; Subat S; Ninomiya H; Nagano H; Nomura K; Okumura S; Ishikawa Y
    Jpn J Clin Oncol; 2016 Oct; 46(10):935-941. PubMed ID: 27511990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.
    Mori S; Motoi N; Ninomiya H; Matsuura Y; Nakao M; Mun M; Okumura S; Nishio M; Morikawa T; Ishikawa Y
    Pathol Int; 2017 Jan; 67(1):37-44. PubMed ID: 27976463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
    Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Nishio M; Okumura S; Ishikawa Y
    Cancer Med; 2017 Oct; 6(10):2347-2356. PubMed ID: 28925087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
    Song Z; Yu X; Cheng G; Zhang Y
    J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma.
    Zaric B; Brcic L; Buder A; Brandstetter A; Buresch JO; Traint S; Kovacevic T; Stojsic V; Perin B; Pirker R; Filipits M
    Clin Lung Cancer; 2018 Nov; 19(6):e957-e963. PubMed ID: 30197262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
    Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
    J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
    Yoon N; Kim J; Maeng LS; Ahn JH; Park ES
    Anticancer Res; 2018 Oct; 38(10):6003-6008. PubMed ID: 30275232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
    Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
    Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with
    Cho JH; Zhou W; Choi YL; Sun JM; Choi H; Kim TE; Dolled-Filhart M; Emancipator K; Rutkowski MA; Kim J
    Cancer Res Treat; 2018 Jan; 50(1):95-102. PubMed ID: 28301925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
    Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
    Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.
    Takamori S; Takada K; Azuma K; Jogo T; Shimokawa M; Toyokawa G; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
    Ann Surg Oncol; 2019 Jun; 26(6):1916-1924. PubMed ID: 30815801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
    Kozuma Y; Takada K; Toyokawa G; Kohashi K; Shimokawa M; Hirai F; Tagawa T; Okamoto T; Oda Y; Maehara Y
    Eur J Cancer; 2018 Sep; 101():20-29. PubMed ID: 30014971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
    Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
    Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
    Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
    Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
    Wu S; Shi X; Sun J; Liu Y; Luo Y; Liang Z; Wang J; Zeng X
    Oncotarget; 2017 Mar; 8(10):16421-16429. PubMed ID: 28145884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
    Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
    Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.